We serve Chemical Name:4-chloro-6-iodopyrimidine CAS:258506-74-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-chloro-6-iodopyrimidine
CAS.NO:258506-74-0
Synonyms:Pyrimidine,4-chloro-6-iodo
Molecular Formula:C4H2ClIN2
Molecular Weight:240.43000
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:268.84ºC at 760 mmHg
Density:2.188g/cm3
Index of Refraction:1.653
PSA:25.78000
Exact Mass:239.89500
LogP:1.73460
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Pyrimidine,4-chloro-6-iodo chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Pyrimidine,4-chloro-6-iodo physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pyrimidine,4-chloro-6-iodo Use and application,Pyrimidine,4-chloro-6-iodo technical grade,usp/ep/jp grade.
Related News: Many domestic raw material pharmaceutical and intermediate manufacturing companies with strong capital and talent reserves and advanced technology and processes have developed in the country, and the competitiveness of market participants has continued to increase. 4-chloro-6-iodopyrimidine manufacturer ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy. 4-chloro-6-iodopyrimidine supplier Many domestic raw material pharmaceutical and intermediate manufacturing companies with strong capital and talent reserves and advanced technology and processes have developed in the country, and the competitiveness of market participants has continued to increase. 4-chloro-6-iodopyrimidine vendor ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy. 4-chloro-6-iodopyrimidine factory Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.
